Compare PTCT & BB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PTCT | BB |
|---|---|---|
| Founded | 1998 | 1984 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 6.0B |
| IPO Year | 2006 | 1999 |
| Metric | PTCT | BB |
|---|---|---|
| Price | $82.28 | $11.42 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 17 | 4 |
| Target Price | ★ $80.65 | $4.85 |
| AVG Volume (30 Days) | 2.2M | ★ 39.2M |
| Earning Date | 05-07-2026 | 04-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 264.48 | 169.23 |
| EPS | N/A | ★ 0.09 |
| Revenue | $264,734,000.00 | ★ $549,100,000.00 |
| Revenue This Year | N/A | $12.21 |
| Revenue Next Year | $17.70 | $8.95 |
| P/E Ratio | ★ N/A | $127.89 |
| Revenue Growth | ★ 36.19 | 2.65 |
| 52 Week Low | $43.18 | $3.12 |
| 52 Week High | $87.50 | $13.59 |
| Indicator | PTCT | BB |
|---|---|---|
| Relative Strength Index (RSI) | 65.15 | 64.43 |
| Support Level | $73.41 | $3.74 |
| Resistance Level | $87.27 | N/A |
| Average True Range (ATR) | 3.11 | 0.90 |
| MACD | 0.22 | 0.23 |
| Stochastic Oscillator | 75.57 | 61.34 |
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
BlackBerry, once known for being the world's largest smartphone manufacturer, is now exclusively a software provider with a stated goal of end-to-end secure communications for enterprises. The firm provides endpoint management and other secure communications software to enterprises, specializing in regulated industries like government and financial institutions. BlackBerry also has a sizable embedded software business primarily serving the automotive market, with some exposure to the industrial market.